Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: "The Clinton Foundation might be committed to doing good around the world, but Hillary Clinton's critics see it as a ripe target to bring down the presumptive Democratic nominee. Republican Donald Trump recently charged that some countries who gave money to the foundation received favorable treatment in return. For anyone who hasn't heard about the Clinton Foundation, it's the signature project to reduce poverty and improve global health created by former President Bill Clinton. It is part matchmaker, helping wealthy donors connect with doers, and part active participant, directly running programs, especially in health care. In an interview with Hillary Clinton, CNN's Anderson Cooper quoted Trump and asked if her husband would break all ties with the foundation, should she become president. Clinton said she would cross that bridge ""if we come to it,"" and proceeded to give a full-throated defense of the foundation. ""I'm proud of the work that it has done,"" Clinton said in the June 8, 2016, interview. ""Nine million people have lower-cost HIV/AIDS medicine because of the work of the Clinton Foundation and my husband. We have women across the country, from Latin America and Africa -- across the world, I mean -- getting good jobs, and being able to support themselves for the first time."" We'll focus on the first part of that statement and explore if the Clinton Foundation actually had a hand in making HIV/AIDS drugs more affordable for 9 million people? The foundation's work on HIV/AIDS treatment dates back to 2002 with the creation of the Clinton Health Access Initiative. That was a time when some countries were paying $1,000 or more to treat each AIDS patient. The basic goal was to bring in bulk-buying to lower costs. The program consolidated both the supply of raw materials to make the drugs and the bidding to supply the finished product. The result was lower production costs and lower drug prices. Today, the initiative tracks the going price for a menu of treatments and posts them to help health departments around the world as they negotiate with drug companies. In 2014, the World Health Organization reported that by the end of 2013, more than 11.7 million people were on antiretroviral therapy in low- and middle-income countries. While the kinds of drugs have changed, the WHO said ""in the past decade the price of individual antiretroviral formulations has decreased considerably."" The treatments used in the early days have fallen from a median cost of about $600 in 2003 to about $100 a decade later. A more advanced drug combination introduced in 2005 saw a similar decline. Importantly, the WHO listed the Clinton Health Access Initiative as one of a handful of organizations collaborating on ensuring a steady supply of drugs. The partners in that effort include the biggest players, including several United Nations agencies, PEPFAR (the President's Emergency Plan for AIDS Relief) and UNITAID, a project created by Brazil, Chile, France, Norway and the United Kingdom. UNAIDS announced at the end of May that the number of people under treatment is now closer to 17 million. Technically, the Clinton Health Access Initiative has been a separate nonprofit since 2010, but it is still integrated within the Clinton Foundation and the foundation press office still offers comments on its behalf. Clinton Health Access Initiativespokeswoman Maura Daley told us that Clinton used an old figure for the people being served by the initiative. ""The total number of patients benefitting is 11.8 million,"" she told us. Not everyone getting treatment is counted as benefiting from the initiative's efforts. Beyond working to reduce drug costs, it also coordinates with nongovernmental organizations inside countries to distribute the drugs once they arrive. Clearly, the Clinton Health Access Initiative did not accomplish all of this on its own, but Clinton didn't say that. Two experts in HIV/AIDS treatment, Jennifer Kates at the Kaiser Family Foundation, and Ellen 't Hoen call the initiative an important player. 't Hoen was the first executive director of the Medicines Patent Pool, a group that streamlines the production of generic antiretroviral drugs. ""Without the work of the MPP it would have been much harder for organizations like CHAI to access generic antiretrovirals,"" she said. The initiative has been faulted for failing to fully report donations from foreign governmentsand has filed amended returns for 2012 and 2013. Our ruling Clinton said 9 million people have lower-cost HIV/AIDS medicine thanks to the efforts of the Clinton Foundation and her husband. Bill Clinton started the foundation and its first big project was the Clinton Health Access Initiative. The program focused on using market mechanisms to reduce treatment costs. Costs have fallen dramatically and the initiative remains a key global player in maintaining a steady supply of affordable drugs. If anything, Clinton understated the number of people who have benefited from the program.

Output: Nine million people have lower-cost HIV/AIDS medicine because of the work of the Clinton Foundation and my husband.

Input: Consider Input: The Trump administration has called for 30 days of measures, including staying at least six feet away from other people, that have upended American life as most people stay isolated at home, shuttering schools and closing businesses through at least the end of April, with some states continuing certain closures through May and June. Dr. Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases, said such steps must continue but that there are hopeful signs they are working. "If in fact we are successful, it makes sense to at least plan what a re-entry into normality would look like. That doesn't mean we're going to do it right now, but it means we need to be prepared to ease into that," Fauci, a member of the White House coronavirus task force, told Fox News in an interview. Fauci and other public health experts have said the strict measures are needed to control the fast-spreading and potentially fatal disease that has already led to about 400,000 confirmed COVID-19 U.S. cases and nearly 13,000 deaths, even as the shutdowns have roiled the U.S. economy. Dr. Deborah Birx, another task force member, said isolation measures must continue for now or else the country could risk a repeated spike despite the allure of warmer spring weather. "What's really important is that people don't turn these early signs of hope into releasing from the 30 days to stop the spread. It's really critical," she told NBC News' "Today" program. "If people start going out again and socially interacting, we could see a really acute second wave." Asked if 30-day distancing practices would be enough or that steps might have to continue longer, she said officials were looking at each area of the country differently as they weigh the data. "Clearly, there are metro areas that are struggling," Birx said.

Output: U.S. planning ways to 'ease' back to normal if virus efforts work: Fauci.

Input: Consider Input: A cost for the medications discussed was provided; in addition the story noted that niacin was available in a less expensive, generic version. The story adequately discussed the benefits observed in this study, in a somewhat scattered fashion. It mentioned the difference in heart attacks and other heart problems observed and though they were few, the difference was statistically significant. The story does note the issues related to the surrogate endpoint and puts the study into context. The use ofa spokesperson from the manufacturer of eztimibe in comments on the value of the surrogate endpoint is curious and takes away from the legitimate discussion on its value. This is offset somewhat by the comments of another presumably less conflicted expert. The side effect, flushing, associate with naicin was mentioned in the story as well as an estimate (1/3 of those taking Niaspan) for how many in the study were affected. The story provided information about the study in a piece meal fashion which included the number of individuals studied and that the study was stopped early because one group appeared to be faring better than the other with respect to size of carotid plaque. A comment from a representative of the other drug makers mentioned that the end point (size of plaque buildup in the carotid) needs to followed up on because in and of itself does not have a health impact. Coming from him it almost seemed as though it was sour grapes, but it is a very valid concern for interpreting the results of the study. It would have been better to have a less involved expert comment on the surrogate endpoint/ The story did not engage in overt disease mongering. Comments from several expert sources outside of the study investigators or the manufacturer of the drug that appear to provide a better outcome were included in this story. The story discussed several of the available medications that could be used in addition to statins to lower heart attack risk. It might have been useful to include some information about dietary and lifestyle changes that could also be used to lower heart attack risk. The story made it very clear that the medications discussed are all currently commercially available. None of the medicines discussed in this story are new or novel and they were not presented as such. Does not appear to rely exclusively on a press release.
Output: Niacin shrinks artery plaque; Merck's Zetia does not and may carry risks, new study finds